Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Transgenic blockade of interleukin 6 transsignaling abrogates inflammation

Rabe, Bjorn, Chalaris, Athena, May, Ulrike, Waetzig, Georg H., Seegert, Dirk, Williams, Anwen Sian, Jones, Simon Arnett, Rose-John, Stefan and Scheller, Jurgen 2008. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111 (3) , pp. 1021-1028. 10.1182/blood-2007-07-102137

Full text not available from this repository.


The immunoregulatory cytokine Interleukin-6 (IL6) acts in a pro- and anti-inflammatory fashion. Synthesized by myeloid cells, fibroblasts and endothelial cells, IL6 on target cells, binds to the IL6 receptor (IL6R) and signals via complex formation with the ubiquitously expressed gp130 receptor. Paradoxically, most cells, which respond to IL6 during inflammatory states do not express the IL6R and are themselves not directly responsive to the cytokine. A naturally occurring soluble form of the IL6R renders all cells responsive to IL6. This alternative signaling process is called IL6-trans-signaling. Here we developed a transgenic strategy based on the overexpression of the soluble form of gp130, which specifically blocks all IL6 responses mediated by the soluble IL6R but does not affect IL6 responses via the membrane bound IL6R. In these mice, inflammatory processes are blocked as in IL6-/- mice strongly arguing for a major role of the soluble IL6R during inflammation in vivo.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Systems Immunity Research Institute (SIURI)
Subjects: Q Science > QR Microbiology > QR180 Immunology
R Medicine > RC Internal medicine
Publisher: American Society of Hematology
ISSN: 0006-4971
Last Modified: 08 Aug 2018 20:20

Citation Data

Cited 201 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item